ValiRx plc (LON:VAL – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 1.36 ($0.02) and last traded at GBX 1.50 ($0.02), with a volume of 582931 shares. The stock had previously closed at GBX 1.50 ($0.02).
ValiRx Price Performance
The stock has a market cap of £1.99 million, a price-to-earnings ratio of -68.00 and a beta of 0.59. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.27 and a current ratio of 2.64. The business’s fifty day simple moving average is GBX 2.20 and its 200 day simple moving average is GBX 2.77.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Read More
- Five stocks we like better than ValiRx
- ESG Stocks, What Investors Should Know
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Trading Stocks: RSI and Why it’s Useful
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Stock Market Sectors: What Are They and How Many Are There?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
